Loading...
XNAS
SVRA
Market cap1.32bUSD
Dec 05, Last price  
6.50USD
1D
2.04%
1Q
74.73%
Jan 2017
6.98%
IPO
-90.19%
Name

Savara Inc

Chart & Performance

D1W1MN
XNAS:SVRA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
37.70%
Rev. gr., 5y
25.99%
Revenues
0k
496,0590500,000500,000300,000488,9590001,54854400,000000257,0000000
Net income
-96m
L+75.29%
-24,782,646-29,331,773-22,142,040-26,647,493-11,325,058-8,450,922-13,260,000-15,559,489-21,480,285-28,702,000-39,842,000-10,923,000-29,797,000-61,516,000-105,025,000-51,097,000-45,296,000-38,946,000-54,698,000-95,881,000
CFO
-89m
L+74.47%
-11,646,829-15,773,544-19,643,190-23,787,604-12,616,416-8,341,237-13,466,954-13,918,868-17,788,962-24,645,000-32,949,000-8,370,000-28,234,000-39,275,000-45,123,000-39,836,000-40,081,000-34,554,000-51,061,000-89,088,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
URL
http://savarapharma.com/
IPO date
Jun 25, 2001
Employees
28
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT